1.
Oncoimmunology
; 4(12): e1054600, 2015 Dec.
Article
in English
| MEDLINE
| ID: mdl-26587333
ABSTRACT
All immunoregulatory chemotherapeutics are chiefly applied in a systemic setting for anticancer therapy. However, immune responses following loco-regional application of chemotherapy may differ from those after systemic application. We recently found that Melphalan, a prototypical loco-regionally applied chemotherapeutic agent, exhibits the ability to increase the immunogenicity of dying melanoma cells.